Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSV | O60911 | 2/20 | 0.37 |
| ▸ | CTSS | P25774 | 2/20 | 0.37 |
| ▸ | CTSK | P43235 | 2/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | DPP4 | P27487 | 3/20 | 0.36 |
| ▸ | CTSL | P07711 | 1/20 | 0.36 |
| ▸ | CTSB | P07858 | 1/20 | 0.36 |
| ▸ | ELANE | P08246 | 1/20 | 0.36 |
| ▸ | CMA1 | P23946 | 1/20 | 0.36 |
| ▸ | CTSF | Q9UBX1 | 1/20 | 0.36 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.36 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25135486 | 0.93 | DPP4 (0.40) | CTSVCTSSCTSKDPP4CTSL | |
| SCHEMBL8188346 | 0.93 | DPP4 (0.40) | CTSVCTSSCTSKDPP4CTSL | |
| SCHEMBL30705634 | 0.93 | DPP4 (0.40) | CTSVCTSSCTSKDPP4CTSL | |
| SCHEMBL12142684 | 0.93 | DPP4 (0.40) | CTSVCTSSCTSKDPP4CTSL | |
| SCHEMBL7724507 | 0.93 | DPP4 (0.40) | CTSVCTSSCTSKDPP4CTSL | |
| Hydrochloric Acid SCHEMBL25310550 | 0.92 | DPP4 (0.39) | CTSVCTSSCTSKDPP4CTSL | |
| Hydrochloric Acid SCHEMBL25310545 | 0.92 | DPP4 (0.39) | CTSVCTSSCTSKDPP4CTSL | |
| Trifluoroacetic Acid SCHEMBL25271188 | 0.89 | DPP4 (0.38) | CTSVCTSSCTSKCYP3A4DPP4 | |
| Trifluoroacetic Acid SCHEMBL29894802 | 0.88 | DPP4 (0.35) | CTSVCTSSCTSKCYP3A4DPP4 | |
| SCHEMBL25271187 | 0.85 | DPP4 (0.36) | CTSVCTSSCTSKCYP3A4DPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250074938-A1 | CELL-PERMEANT INHIBITORS OF VIRAL CYSTEINE PROTEASES | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2025-03-06 | — | — | US | disclosed |
| WO-2023114516-A2 | CELL-PERMEANT INHIBITORS OF VIRAL CYSTEINE PROTEASES | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2023-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250074938-A1 | CELL-PERMEANT INHIBITORS OF VIRAL CYSTEINE PROTEASES | ACE, TMPRSS2, ACE2 | CTSV 7/4885CTSS 12/4885CTSK 54/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.